Home › Triple-Negative Breast Cancer › Massachusetts › Boston

Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Boston, MA

26 pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Boston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 12 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 19 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06586957

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Nagre-recruitPhase 1

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05422794

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Nagre-recruitPhase 3

Massachusetts General Hospital Cancer Center ( Site 0091), Boston
Dana Farber Cancer Institute ( Site 0090), Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06966700

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

Nagre-recruit

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07513311

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06657222

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Nagre-recruitPhase 3

Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05633654

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Nagre-recruitPhase 1

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07029399

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Nagre-recruitPhase 1

Normunity Investigational Site, Boston
Normunity Investigational Site, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07182149

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Nagre-recruitPhase 1

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07341867

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Nagre-recruitPhase 2/3

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06926868

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Nagre-recruitPhase 2

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06176261

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT05579366

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT06562192

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Nagre-recruitPhase 1

Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT06150664

Sacituzumab Govitecan In TNBC

Nagre-recruitPhase 2

Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT04230109

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Nagre-recruitPhase 1

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT07137416

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Nagre-recruitPhase 1/2

Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT05377996

A Study of LY4175408 in Participants With Advanced Cancer

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT07046923

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Nagre-recruitPhase 2

Dana-Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update May 4, 2026 · NCT04434040

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Nagre-recruitPhase 2

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 29, 2026 · NCT04468061

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Nagre-recruitPhase 1

Dana Farber Cancer Institute, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT06451497

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Nagre-recruitPhase 1

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06908928

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Nagre-recruitPhase 1/2

Massachusetts General Hospital, Boston

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 15, 2024 · NCT04787042

Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod

Iba pang pag-aaral sa Boston

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.